{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:46:51Z","timestamp":1794361611170,"version":"4.9.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T00:00:00Z","timestamp":1580860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI052417"],"award-info":[{"award-number":["AI052417"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI104521"],"award-info":[{"award-number":["AI104521"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI126036"],"award-info":[{"award-number":["AI126036"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases"},{"DOI":"10.13039\/501100003785","name":"Guangdong Medical Research Foundation","doi-asserted-by":"publisher","award":["A2018300"],"award-info":[{"award-number":["A2018300"]}],"id":[{"id":"10.13039\/501100003785","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["CA013696"],"award-info":[{"award-number":["CA013696"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI104688"],"award-info":[{"award-number":["AI104688"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | National Institutes of Health"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Adult T-cell leukemia\/lymphoma (ATLL) is a malignancy of mature T cells associated with chronic infection by human T-cell lymphotropic virus type-1 (HTLV-1). ATLL patients with aggressive subtypes have dismal outcomes. We demonstrate that ATLL cells co-opt an early checkpoint within the tumor necrosis factor receptor 1 (TNFR1) pathway, resulting in survival advantage. This early checkpoint revolves around an interaction between the deubiquitinase CYLD and its target RIPK1. The status of RIPK1 K63-ubiquitination determines cell fate by creating either a prosurvival signal (ubiquitinated RIPK1) or a death signal (deubiquitinated RIPK1). In primary ATLL samples and in cell line models, an increased baseline level of CYLD phosphorylation was observed. We therefore tested the hypothesis that this modification of CYLD, which has been reported to inhibit its deubiquitinating function, leads to increased RIPK1 ubiquitination and thus provides a prosurvival signal to ATLL cells. CYLD phosphorylation can be pharmacologically reversed by IKK inhibitors, specifically by TBK1\/IKK\u03b5 and IKK\u03b2 inhibitors (MRT67307 and TPCA). Both of the IKK sub-families can phosphorylate CYLD, and the combination of MRT67307 and TPCA have a marked effect in reducing CYLD phosphorylation and triggering cell death. ATLL cells overexpressing a kinase-inactive TBK1 (TBK1-K38A) demonstrate lower CYLD phosphorylation and subsequently reduced proliferation. IKK blockade reactivates CYLD, as evidenced by the reduction in RIPK1 ubiquitination, which leads to the association of RIPK1 with the death-inducing signaling complex (DISC) to trigger cell death. In the absence of CYLD, RIPK1 ubiquitination remains elevated following IKK blockade and it does not associate with the DISC. SMAC mimetics can similarly disrupt CYLD phosphorylation and lead to ATLL cell death through reduction of RIPK1 ubiquitination, which is CYLD dependent. These results identify CYLD as a crucial regulator of ATLL survival and point to its role as a potential novel target for pharmacologic modification in this disease.<\/jats:p>","DOI":"10.1038\/s41419-020-2294-6","type":"journal-article","created":{"date-parts":[[2020,2,5]],"date-time":"2020-02-05T12:02:46Z","timestamp":1580904166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia\/lymphoma (ATLL)"],"prefix":"10.1038","volume":"11","author":[{"given":"Xin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matko","family":"Kalac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Markson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0850-6730","authenticated-orcid":false,"given":"Joshua D.","family":"Brody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6250-048X","authenticated-orcid":false,"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalind L.","family":"Ang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Legarda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Justus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingshan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabao","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-9923","authenticated-orcid":false,"given":"Adrian T.","family":"Ting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,5]]},"reference":[{"key":"2294_CR1","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1038\/nature01648","volume":"423","author":"V Anest","year":"2003","unstructured":"Anest, V. et al. A nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene expression. Nature 423, 659\u2013663 (2003).","journal-title":"Nature"},{"key":"2294_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrc2111","volume":"7","author":"M Matsuoka","year":"2007","unstructured":"Matsuoka, M. & Jeang, K. T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat. Rev. Cancer 7, 270\u2013280 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"2294_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004454","volume":"10","author":"CA Pise-Masison","year":"2014","unstructured":"Pise-Masison, C. A. et al. Co-dependence of HTLV-1 p12 and p8 functions in virus persistence. PLoS Pathog. 10, e1004454 (2014).","journal-title":"PLoS Pathog."},{"key":"2294_CR4","doi-asserted-by":"publisher","first-page":"20738","DOI":"10.1073\/pnas.1009635107","volume":"107","author":"N Van Prooyen","year":"2010","unstructured":"Van Prooyen, N. et al. Human T-cell leukemia virus type 1 p8 protein increases cellular conduits and virus transmission. Proc. Natl Acad. Sci. USA 107, 20738\u201320743 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2294_CR5","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1098\/rstb.2000.0638","volume":"355","author":"B Asquith","year":"2000","unstructured":"Asquith, B., Hanon, E., Taylor, G. P. & Bangham, C. R. Is human T-cell lymphotropic virus type I really silent? Philos. Trans. R. Soc. Lond. B Biol. Sci. 355, 1013\u20131019 (2000).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"2294_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-1-20","volume":"1","author":"I Azran","year":"2004","unstructured":"Azran, I., Schavinsky-Khrapunsky, Y. & Aboud, M. Role of Tax protein in human T-cell leukemia virus type-I leukemogenicity. Retrovirology 1, 20 (2004).","journal-title":"Retrovirology"},{"key":"2294_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.coviro.2015.09.004","volume":"14","author":"CR Bangham","year":"2015","unstructured":"Bangham, C. R. & Ratner, L. How does HTLV-1 cause adult T-cell leukaemia\/lymphoma (ATL)? Curr. Opin. Virol. 14, 93\u2013100 (2015).","journal-title":"Curr. Opin. Virol."},{"key":"2294_CR8","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/S0145-2126(99)00193-9","volume":"24","author":"V Ciminale","year":"2000","unstructured":"Ciminale, V. et al. Unusual CD4+CD8+ phenotype in a greek patient diagnosed with adult T-cell leukemia positive for human T-cell leukemia virus type I (HTLV-I). Leuk. Res. 24, 353\u2013358 (2000).","journal-title":"Leuk. Res."},{"key":"2294_CR9","doi-asserted-by":"crossref","first-page":"6674","DOI":"10.4049\/jimmunol.161.12.6674","volume":"161","author":"N Eiraku","year":"1998","unstructured":"Eiraku, N. et al. Clonal expansion within CD4+ and CD8+ T cell subsets in human T lymphotropic virus type I-infected individuals. J. Immunol. 161, 6674\u20136680 (1998).","journal-title":"J. Immunol."},{"key":"2294_CR10","doi-asserted-by":"publisher","first-page":"5682","DOI":"10.1128\/JVI.64.11.5682-5687.1990","volume":"64","author":"JH Richardson","year":"1990","unstructured":"Richardson, J. H., Edwards, A. J., Cruickshank, J. K., Rudge, P. & Dalgleish, A. G. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol. 64, 5682\u20135687 (1990).","journal-title":"J. Virol."},{"key":"2294_CR11","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fmicb.2012.00406","volume":"3","author":"R Currer","year":"2012","unstructured":"Currer, R. et al. HTLV tax: a fascinating multifunctional co-regulator of viral and cellular pathways. Front. Microbiol. 3, 406 (2012).","journal-title":"Front. Microbiol."},{"key":"2294_CR12","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/blood-2017-01-761874","volume":"131","author":"K Kataoka","year":"2018","unstructured":"Kataoka, K. et al. Prognostic relevance of integrated genetic profiling in adult T-cell leukemia\/lymphoma. Blood 131, 215\u2013225 (2018).","journal-title":"Blood"},{"key":"2294_CR13","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1182\/blood-2016-09-692574","volume":"129","author":"T Watanabe","year":"2017","unstructured":"Watanabe, T. Adult T-cell leukemia: molecular basis for clonal expansion and transformation of HTLV-1-infected T cells. Blood 129, 1071\u20131081 (2017).","journal-title":"Blood"},{"key":"2294_CR14","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","volume":"126","author":"H Katsuya","year":"2015","unstructured":"Katsuya, H. et al. Treatment and survival among 1594 patients with ATL. Blood 126, 2570\u20132577 (2015).","journal-title":"Blood"},{"key":"2294_CR15","doi-asserted-by":"publisher","first-page":"51981","DOI":"10.18632\/oncotarget.10223","volume":"7","author":"M Zell","year":"2016","unstructured":"Zell, M. et al. Adult T-cell leukemia\/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy. Oncotarget 7, 51981\u201351990 (2016).","journal-title":"Oncotarget"},{"key":"2294_CR16","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1038\/bmt.2014.143","volume":"49","author":"A Bazarbachi","year":"2014","unstructured":"Bazarbachi, A. et al. Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP. Bone Marrow Transpl. 49, 1266\u20131268 (2014).","journal-title":"Bone Marrow Transpl."},{"key":"2294_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.57","volume":"3","author":"D Chihara","year":"2013","unstructured":"Chihara, D. et al. Association between decreasing trend in the mortality of adult T-cell leukemia\/lymphoma and allogeneic hematopoietic stem cell transplants in Japan: analysis of Japanese vital statistics and Japan Society for Hematopoietic Cell Transplantation (JSHCT). Blood Cancer J. 3, e159 (2013).","journal-title":"Blood Cancer J."},{"key":"2294_CR18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","volume":"27","author":"K Tsukasaki","year":"2009","unstructured":"Tsukasaki, K. et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. J. Clin. Oncol. 27, 453\u2013459 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2294_CR19","doi-asserted-by":"publisher","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","volume":"28","author":"A Bazarbachi","year":"2010","unstructured":"Bazarbachi, A. et al. Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes. J. Clin. Oncol. 28, 4177\u20134183 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2294_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12185-017-2361-7","volume":"107","author":"LB Cook","year":"2018","unstructured":"Cook, L. B. et al. Long-term clinical remission maintained after cessation of zidovudine and interferon-alpha therapy in chronic adult T-cell leukemia\/lymphoma. Int J. Hematol. 107, 378\u2013382 (2018).","journal-title":"Int J. Hematol."},{"key":"2294_CR21","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","volume":"30","author":"T Ishida","year":"2012","unstructured":"Ishida, T. et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J. Clin. Oncol. 30, 837\u2013842 (2012).","journal-title":"J. Clin. Oncol."},{"key":"2294_CR22","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","volume":"28","author":"K Yamamoto","year":"2010","unstructured":"Yamamoto, K. et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. J. Clin. Oncol. 28, 1591\u20131598 (2010).","journal-title":"J. Clin. Oncol."},{"key":"2294_CR23","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1056\/NEJMc1803181","volume":"378","author":"L Ratner","year":"2018","unstructured":"Ratner, L., Waldmann, T. A., Janakiram, M. & Brammer, J. E. Rapid Progression of Adult T-Cell Leukemia-Lymphoma after PD-1 Inhibitor Therapy. N. Engl. J. Med 378, 1947\u20131948 (2018).","journal-title":"N. Engl. J. Med"},{"key":"2294_CR24","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1182\/blood-2015-10-670489","volume":"126","author":"O Hermine","year":"2015","unstructured":"Hermine, O. ATL treatment: is it time to change? Blood 126, 2533\u20132534 (2015).","journal-title":"Blood"},{"key":"2294_CR25","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/j.1742-4658.2011.08016.x","volume":"278","author":"MA O\u2019Donnell","year":"2011","unstructured":"O\u2019Donnell, M. A. & Ting, A. T. RIP1 comes back to life as a cell death regulator in TNFR1 signaling. FEBS J. 278, 877\u2013887 (2011).","journal-title":"FEBS J."},{"key":"2294_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","volume":"37","author":"AT Ting","year":"2016","unstructured":"Ting, A. T. & Bertrand, M. J. M. More to life than NF-kappaB in TNFR1 signaling. Trends Immunol. 37, 535\u2013545 (2016).","journal-title":"Trends Immunol."},{"key":"2294_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.4161\/cc.9.6.10982","volume":"9","author":"MA O\u2019Donnell","year":"2010","unstructured":"O\u2019Donnell, M. A. & Ting, A. T. Chronicles of a death foretold: dual sequential cell death checkpoints in TNF signaling. Cell Cycle 9, 1065\u20131071 (2010).","journal-title":"Cell Cycle"},{"key":"2294_CR28","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.cub.2007.01.027","volume":"17","author":"MA O\u2019Donnell","year":"2007","unstructured":"O\u2019Donnell, M. A., Legarda-Addison, D., Skountzos, P., Yeh, W. C. & Ting, A. T. Ubiquitination of RIP1 regulates an NF-kappaB-independent cell-death switch in TNF signaling. Curr. Biol. 17, 418\u2013424 (2007).","journal-title":"Curr. Biol."},{"key":"2294_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12304","volume":"266","author":"SJ Justus","year":"2015","unstructured":"Justus, S. J. & Ting, A. T. Cloaked in ubiquitin, a killer hides in plain sight: the molecular regulation of RIPK1. Immunol. Rev. 266, 145\u2013160 (2015).","journal-title":"Immunol. Rev."},{"key":"2294_CR30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.molcel.2008.05.014","volume":"30","author":"MJ Bertrand","year":"2008","unstructured":"Bertrand, M. J. et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 30, 689\u2013700 (2008).","journal-title":"Mol. Cell"},{"key":"2294_CR31","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.ccr.2007.08.029","volume":"12","author":"SL Petersen","year":"2007","unstructured":"Petersen, S. L. et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 12, 445\u2013456 (2007).","journal-title":"Cancer Cell"},{"key":"2294_CR32","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.cell.2008.03.036","volume":"133","author":"L Wang","year":"2008","unstructured":"Wang, L., Du, F. & Wang, X. TNF-alpha induces two distinct caspase-8 activation pathways. Cell 133, 693\u2013703 (2008).","journal-title":"Cell"},{"key":"2294_CR33","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/hep.28723","volume":"64","author":"C Koppe","year":"2016","unstructured":"Koppe, C. et al. IkappaB kinasealpha\/beta control biliary homeostasis and hepatocarcinogenesis in mice by phosphorylating the cell-death mediator receptor-interacting protein kinase 1. Hepatology 64, 1217\u20131231 (2016).","journal-title":"Hepatology"},{"key":"2294_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.molcel.2015.07.032","volume":"60","author":"Y Dondelinger","year":"2015","unstructured":"Dondelinger, Y. et al. NF-kappaB-independent role of IKKalpha\/IKKbeta in preventing RIPK1 kinase-dependent apoptotic and necroptotic cell death during TNF signaling. Mol. Cell 60, 63\u201376 (2015).","journal-title":"Mol. Cell"},{"key":"2294_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09690-0","volume":"10","author":"Y Dondelinger","year":"2019","unstructured":"Dondelinger, Y. et al. Serine 25 phosphorylation inhibits RIPK1 kinase-dependent cell death in models of infection and inflammation. Nat. Commun. 10, 1729 (2019).","journal-title":"Nat. Commun."},{"key":"2294_CR36","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1016\/j.cell.2018.07.041","volume":"174","author":"D Xu","year":"2018","unstructured":"Xu, D. et al. TBK1 suppresses RIPK1-driven apoptosis and inflammation during development and in aging. Cell 174, 1477\u20131491. e1419 (2018).","journal-title":"Cell"},{"key":"2294_CR37","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1038\/s41556-018-0229-6","volume":"20","author":"E Lafont","year":"2018","unstructured":"Lafont, E. et al. TBK1 and IKKepsilon prevent TNF-induced cell death by RIPK1 phosphorylation. Nat. Cell Biol. 20, 1389\u20131399 (2018).","journal-title":"Nat. Cell Biol."},{"key":"2294_CR38","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1038\/ncb3608","volume":"19","author":"Y Dondelinger","year":"2017","unstructured":"Dondelinger, Y. et al. MK2 phosphorylation of RIPK1 regulates TNF-mediated cell death. Nat. Cell Biol. 19, 1237\u20131247 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2294_CR39","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.molcel.2017.05.003","volume":"66","author":"I Jaco","year":"2017","unstructured":"Jaco, I. et al. MK2 phosphorylates RIPK1 to prevent TNF-induced cell death. Mol. Cell 66, 698\u2013710 e695 (2017).","journal-title":"Mol. Cell"},{"key":"2294_CR40","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/ncb3614","volume":"19","author":"MB Menon","year":"2017","unstructured":"Menon, M. B. et al. p38(MAPK)\/MK2-dependent phosphorylation controls cytotoxic RIPK1 signalling in inflammation and infection. Nat. Cell Biol. 19, 1248\u20131259 (2017).","journal-title":"Nat. Cell Biol."},{"key":"2294_CR41","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1007\/s00018-016-2191-4","volume":"73","author":"Y Dondelinger","year":"2016","unstructured":"Dondelinger, Y., Darding, M., Bertrand, M. J. & Walczak, H. Poly-ubiquitination in TNFR1-mediated necroptosis. Cell Mol. Life Sci. 73, 2165\u20132176 (2016).","journal-title":"Cell Mol. Life Sci."},{"key":"2294_CR42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1600-065X.2012.01100.x","volume":"246","author":"EW Harhaj","year":"2012","unstructured":"Harhaj, E. W. & Dixit, V. M. Regulation of NF-kappaB by deubiquitinases. Immunol. Rev. 246, 107\u2013124 (2012).","journal-title":"Immunol. Rev."},{"issue":"7","key":"2294_CR43","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/nri2337","volume":"8","author":"Shao-Cong Sun","year":"2008","unstructured":"Sun, S. C. Deubiquitylation and regulation of the immune response. Nat. Rev. Immunol. 8, 501\u2013511 (2008). [pii]. https:\/\/doi.org\/10.1038\/nri2337.","journal-title":"Nature Reviews Immunology"},{"key":"2294_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/cdd.2009.43","volume":"17","author":"SC Sun","year":"2010","unstructured":"Sun, S. C. CYLD: a tumor suppressor deubiquitinase regulating NF-kappaB activation and diverse biological processes. Cell Death Differ. 17, 25\u201334 (2010).","journal-title":"Cell Death Differ."},{"key":"2294_CR45","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.cell.2008.10.044","volume":"135","author":"J Hitomi","year":"2008","unstructured":"Hitomi, J. et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 135, 1311\u20131323 (2008).","journal-title":"Cell"},{"key":"2294_CR46","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1016\/j.celrep.2016.05.032","volume":"15","author":"D Legarda","year":"2016","unstructured":"Legarda, D. et al. CYLD proteolysis protects macrophages from TNF-mediated auto-necroptosis induced by LPS and licensed by type I IFN. Cell Rep. 15, 2449\u20132461 (2016).","journal-title":"Cell Rep."},{"key":"2294_CR47","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1038\/ncb2362","volume":"13","author":"MA O\u2019Donnell","year":"2011","unstructured":"O\u2019Donnell, M. A. et al. Caspase 8 inhibits programmed necrosis by processing CYLD. Nat. Cell Biol. 13, 1437\u20131442 (2011).","journal-title":"Nat. Cell Biol."},{"key":"2294_CR48","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.molcel.2009.04.031","volume":"34","author":"JE Hutti","year":"2009","unstructured":"Hutti, J. E. et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol. Cell 34, 461\u2013472 (2009).","journal-title":"Mol. Cell"},{"key":"2294_CR49","doi-asserted-by":"publisher","first-page":"3886","DOI":"10.1128\/MCB.25.10.3886-3895.2005","volume":"25","author":"W Reiley","year":"2005","unstructured":"Reiley, W., Zhang, M., Wu, X., Granger, E. & Sun, S. C. Regulation of the deubiquitinating enzyme CYLD by IkappaB kinase gamma-dependent phosphorylation. Mol. Cell Biol. 25, 3886\u20133895 (2005).","journal-title":"Mol. Cell Biol."},{"key":"2294_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2045-3701-1-27","volume":"1","author":"X Wu","year":"2011","unstructured":"Wu, X., Zhang, M. & Sun, S. C. Mutual regulation between deubiquitinase CYLD and retroviral oncoprotein Tax. Cell Biosci. 1, 27 (2011).","journal-title":"Cell Biosci."},{"key":"2294_CR51","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/gcc.20789","volume":"49","author":"A Schmidt","year":"2010","unstructured":"Schmidt, A. et al. Rare occurrence of biallelic CYLD gene mutations in classical Hodgkin lymphoma. Genes Chromosomes Cancer 49, 803\u2013809 (2010).","journal-title":"Genes Chromosomes Cancer"},{"key":"2294_CR52","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1002\/eji.200323650","volume":"33","author":"KL He","year":"2003","unstructured":"He, K. L. & Ting, A. T. Essential role for IKKgamma\/NEMO in TCR-induced IL-2 expression in Jurkat T cells. Eur. J. Immunol. 33, 1917\u20131924 (2003).","journal-title":"Eur. J. Immunol."},{"key":"2294_CR53","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/embor.2008.136","volume":"9","author":"CS Friedman","year":"2008","unstructured":"Friedman, C. S. et al. The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response. EMBO Rep. 9, 930\u2013936 (2008).","journal-title":"EMBO Rep."},{"key":"2294_CR54","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3389\/fcell.2018.00040","volume":"6","author":"M Lork","year":"2018","unstructured":"Lork, M., Kreike, M., Staal, J. & Beyaert, R. Importance of validating antibodies and small compound inhibitors using genetic knockout studies-T cell receptor-induced CYLD phosphorylation by IKKepsilon\/TBK1 as a case study. Front. Cell Dev. Biol. 6, 40 (2018).","journal-title":"Front. Cell Dev. Biol."},{"key":"2294_CR55","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1038\/sj.onc.1208976","volume":"24","author":"SJ Marriott","year":"2005","unstructured":"Marriott, S. J. & Semmes, O. J. Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response. Oncogene 24, 5986\u20135995 (2005).","journal-title":"Oncogene"},{"key":"2294_CR56","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3390\/v3060714","volume":"3","author":"Z Qu","year":"2011","unstructured":"Qu, Z. & Xiao, G. Human T-cell lymphotropic virus: a model of NF-kappaB-associated tumorigenesis. Viruses 3, 714\u2013749 (2011).","journal-title":"Viruses"},{"key":"2294_CR57","doi-asserted-by":"publisher","first-page":"5030","DOI":"10.1158\/1078-0432.CCR-15-0365","volume":"21","author":"S Fulda","year":"2015","unstructured":"Fulda, S. Promises and challenges of smac mimetics as cancer therapeutics. Clin. Cancer Res. 21, 5030\u20135036 (2015).","journal-title":"Clin. Cancer Res."},{"key":"2294_CR58","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/bs.ircmb.2016.09.004","volume":"330","author":"S Fulda","year":"2017","unstructured":"Fulda, S. Smac mimetics to therapeutically target IAP proteins in cancer. Int Rev. Cell Mol. Biol. 330, 157\u2013169 (2017).","journal-title":"Int Rev. Cell Mol. Biol."},{"key":"2294_CR59","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.molcel.2006.03.026","volume":"22","author":"CK Ea","year":"2006","unstructured":"Ea, C. K., Deng, L., Xia, Z. P., Pineda, G. & Chen, Z. J. Activation of IKK by TNFalpha requires site-specific ubiquitination of RIP1 and polyubiquitin binding by NEMO. Mol. Cell 22, 245\u2013257 (2006).","journal-title":"Mol. Cell"},{"key":"2294_CR60","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ccr.2010.08.006","volume":"18","author":"L Espinosa","year":"2010","unstructured":"Espinosa, L. et al. The Notch\/Hes1 pathway sustains NF-kappaB activation through CYLD repression in T cell leukemia. Cancer Cell 18, 268\u2013281 (2010).","journal-title":"Cancer Cell"},{"key":"2294_CR61","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1093\/carcin\/bgl081","volume":"28","author":"C Hellerbrand","year":"2007","unstructured":"Hellerbrand, C. et al. Reduced expression of CYLD in human colon and hepatocellular carcinomas. Carcinogenesis 28, 21\u201327 (2007).","journal-title":"Carcinogenesis"},{"key":"2294_CR62","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1084\/jem.20082044","volume":"206","author":"R Massoumi","year":"2009","unstructured":"Massoumi, R. et al. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med 206, 221\u2013232 (2009).","journal-title":"J. Exp. Med"},{"key":"2294_CR63","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1182\/blood-2007-02-075069","volume":"110","author":"MW Jenner","year":"2007","unstructured":"Jenner, M. W. et al. Gene mapping and expression analysis of 16q loss of heterozygosity identifies WWOX and CYLD as being important in determining clinical outcome in multiple myeloma. Blood 110, 3291\u20133300 (2007).","journal-title":"Blood"},{"key":"2294_CR64","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.ccr.2007.07.003","volume":"12","author":"JJ Keats","year":"2007","unstructured":"Keats, J. J. et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell 12, 131\u2013144 (2007).","journal-title":"Cancer Cell"},{"key":"2294_CR65","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1038\/onc.2016.368","volume":"36","author":"H van Andel","year":"2017","unstructured":"van Andel, H. et al. Loss of CYLD expression unleashes Wnt signaling in multiple myeloma and is associated with aggressive disease. Oncogene 36, 2105\u20132115 (2017).","journal-title":"Oncogene"},{"key":"2294_CR66","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1038\/nature01576","volume":"423","author":"Y Yamamoto","year":"2003","unstructured":"Yamamoto, Y., Verma, U. N., Prajapati, S., Kwak, Y. T. & Gaynor, R. B. Histone H3 phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. Nature 423, 655\u2013659 (2003).","journal-title":"Nature"},{"key":"2294_CR67","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.cell.2012.12.021","volume":"152","author":"J Yan","year":"2013","unstructured":"Yan, J. et al. Inactivation of BAD by IKK inhibits TNFalpha-induced apoptosis independently of NF-kappaB activation. Cell 152, 304\u2013315 (2013).","journal-title":"Cell"},{"key":"2294_CR68","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1038\/sj.onc.1208969","volume":"24","author":"SC Sun","year":"2005","unstructured":"Sun, S. C. & Yamaoka, S. Activation of NF-kappaB by HTLV-I and implications for cell transformation. Oncogene 24, 5952\u20135964 (2005).","journal-title":"Oncogene"},{"key":"2294_CR69","doi-asserted-by":"publisher","first-page":"22911","DOI":"10.1074\/jbc.274.33.22911","volume":"274","author":"EW Harhaj","year":"1999","unstructured":"Harhaj, E. W. & Sun, S. C. IKKgamma serves as a docking subunit of the IkappaB kinase (IKK) and mediates interaction of IKK with the human T-cell leukemia virus Tax protein. J. Biol. Chem. 274, 22911\u201322914 (1999).","journal-title":"J. Biol. Chem."},{"key":"2294_CR70","doi-asserted-by":"publisher","first-page":"15891","DOI":"10.1074\/jbc.273.26.15891","volume":"273","author":"ZL Chu","year":"1998","unstructured":"Chu, Z. L., DiDonato, J. A., Hawiger, J. & Ballard, D. W. The tax oncoprotein of human T-cell leukemia virus type 1 associates with and persistently activates IkappaB kinases containing IKKalpha and IKKbeta. J. Biol. Chem. 273, 15891\u201315894 (1998).","journal-title":"J. Biol. Chem."},{"key":"2294_CR71","doi-asserted-by":"publisher","first-page":"17402","DOI":"10.1074\/jbc.274.25.17402","volume":"274","author":"DY Jin","year":"1999","unstructured":"Jin, D. Y., Giordano, V., Kibler, K. V., Nakano, H. & Jeang, K. T. Role of adapter function in oncoprotein-mediated activation of NF- kappaB. Human T-cell leukemia virus type I Tax interacts directly with IkappaB kinase gamma. J. Biol. Chem. 274, 17402\u201317405 (1999).","journal-title":"J. Biol. Chem."},{"key":"2294_CR72","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2011.25","volume":"2","author":"HH Cheung","year":"2011","unstructured":"Cheung, H. H. et al. SMG1 and NIK regulate apoptosis induced by Smac mimetic compounds. Cell Death Dis. 2, e146 (2011).","journal-title":"Cell Death Dis."},{"key":"2294_CR73","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/cdd.2011.10","volume":"18","author":"M Darding","year":"2011","unstructured":"Darding, M. et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ. 18, 1376\u20131386 (2011).","journal-title":"Cell Death Differ."},{"key":"2294_CR74","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1198946","volume":"331","author":"S Rosebeck","year":"2011","unstructured":"Rosebeck, S. et al. Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-kappaB activation. Science 331, 468\u2013472 (2011).","journal-title":"Science"},{"key":"2294_CR75","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"2294_CR76","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.4049\/jimmunol.175.5.2814","volume":"175","author":"M Yang","year":"2005","unstructured":"Yang, M. et al. B cell maturation antigen, the receptor for a proliferation-inducing ligand and B cell-activating factor of the TNF family, induces antigen presentation in B cells. J. Immunol. 175, 2814\u20132824 (2005).","journal-title":"J. Immunol."},{"key":"2294_CR77","doi-asserted-by":"publisher","first-page":"6034","DOI":"10.1128\/MCB.22.17.6034-6045.2002","volume":"22","author":"KL He","year":"2002","unstructured":"He, K. L. & Ting, A. T. A20 inhibits tumor necrosis factor (TNF) alpha-induced apoptosis by disrupting recruitment of TRADD and RIP to the TNF receptor 1 complex in Jurkat T cells. Mol. Cell Biol. 22, 6034\u20136045 (2002).","journal-title":"Mol. Cell Biol."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2294-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2294-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:38:44Z","timestamp":1722393524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-020-2294-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,5]]},"references-count":77,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["2294"],"URL":"https:\/\/doi.org\/10.1038\/s41419-020-2294-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,5]]},"assertion":[{"value":"31 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"94"}}